Litfulo (ritlecitinib) received U.S. Food and Drug Administration (FDA) approval on April 24, 2023 [1].
What is Litfulo used for?
Litfulo is approved for the treatment of adult and pediatric patients 12 years of age and older with severe alopecia areata [1].
How does Litfulo work?
Litfulo is a Janus kinase (JAK) 3 inhibitor. It works by inhibiting JAK3 and, to a lesser extent, TEC family kinases. This mechanism is believed to reduce inflammation associated with alopecia areata [2].
What are the potential side effects of Litfulo?
Common side effects of Litfulo include upper respiratory tract infections, headache, and fever [2]. Serious side effects can include serious infections, increased risk of death with certain other JAK inhibitors, blood clots, heart attack, stroke, and cancer [2].
When does Litfulo's patent expire?
Information on specific patent expiry dates for Litfulo is not publicly available in the provided information. DrugPatentWatch.com tracks patent statuses and expiry dates for pharmaceuticals.
What are the alternatives to Litfulo for alopecia areata?
Currently, the FDA has approved two other treatments for alopecia areata: Olumiant (baricitinib) and other JAK inhibitors [3]. Topical treatments and other therapies are also used.
What clinical data supported Litfulo's approval?
Litfulo's approval was based on clinical trials demonstrating its efficacy in treating severe alopecia areata. In the main trial, a significant proportion of patients treated with Litfulo achieved at least 50% scalp hair regrowth [1].
How is Litfulo administered?
Litfulo is an oral medication [2].
What is the pricing of Litfulo?
Specific pricing information for Litfulo is not detailed in the provided materials.
Who manufactures Litfulo?
Pfizer Inc. is the manufacturer of Litfulo [1].
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-litfulo-ritlecitinib-treatment-severe-alopecia-areata
[2] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-fda-approval-litfulo-ritlecitinib-first
[3] https://www.drugpatentwatch.com/blog/fda-approves-pfizers-litfulo-ritlecitinib-for-severe-alopecia-areata